Clive S. Zent, MD

Professor of Medicine
Wilmot Cancer Institute / University of Rochester Medical Center

N/A

Poster(s):

• 1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)

• 1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10